keyword
MENU ▼
Read by QxMD icon Read
search

Prodromal AD

keyword
https://www.readbyqxmd.com/read/28336337/mismatch-negativity-as-a-potential-neurobiological-marker-of-early-stage-alzheimer-disease-and-vascular-dementia
#1
Shixiang Jiang, Chang Yan, Zhengxue Qiao, Haiqian Yao, Shiquan Jiang, Xiaohui Qiu, Xiuxian Yang, Deyu Fang, Yanjie Yang, Limei Zhang, Lina Wang, Liming Zhang
Alzheimer's disease (AD) and vascular dementia (VD) are serious, irreversible forms of cognitive impairment, which means that an early diagnosis is essential to slow down their progression. One potential neurophysiological biomarker of these diseases is the mismatch negativity (MMN) event-related potentials (ERP) component, which reflects an automatic detection mechanism at the pre-attentive stages of information processing. We evaluated the auditory MMN response in individuals from two patient groups: those in the prodromal stages of AD (P-AD) and those in the prodromal stages of VD (P-VD)...
March 20, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28324341/beta-amyloid-deposition-in-patients-with-major-depressive-disorder-with-differing-levels-of-treatment-resistance-a-pilot-study
#2
Peng Li, Ing-Tsung Hsiao, Chia-Yih Liu, Chia-Hsiang Chen, She-Yao Huang, Tzu-Chen Yen, Kuan-Yi Wu, Kun-Ju Lin
BACKGROUND: Lack of treatment response in patients with late-life depression is common. The role of brain beta-amyloid (Aβ) deposition in treatment outcome in subjects with late-life depression remains unclear. The present study aimed to investigate brain Aβ deposition in patients with major depressive disorder (MDD) with differing treatment outcomes in vivo using (18)F-florbetapir imaging. This study included 62 MDD patients and 18 healthy control subjects (HCs).We first employed the Maudsley staging method (MSM) to categorize MDD patients into two groups according to treatment response: mild treatment resistance (n = 29) and moderate-to-severe treatment resistance (n = 33)...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28317649/clinical-validity-of-cerebrospinal-fluid-a%C3%AE-42-tau-and-phospho-tau-as-biomarkers-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#3
REVIEW
Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson
Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317648/clinical-validity-of-brain-fluorodeoxyglucose-positron-emission-tomography-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#4
REVIEW
Valentina Garibotto, Karl Herholz, Marina Boccardi, Agnese Picco, Andrea Varrone, Agneta Nordberg, Flavio Nobili, Osman Ratib
The use of Alzheimer's disease (AD) biomarkers is supported in diagnostic criteria, but their maturity for clinical routine is still debated. Here, we evaluate brain fluorodeoxyglucose positron emission tomography (FDG PET), a measure of cerebral glucose metabolism, as a biomarker to identify clinical and prodromal AD according to the framework suggested for biomarkers in oncology, using homogenous criteria with other biomarkers addressed in parallel reviews. FDG PET has fully achieved phase 1 (rational for use) and most of phase 2 (ability to discriminate AD subjects from healthy controls or other forms of dementia) aims...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28290246/spatio-temporal-fluctuations-of-neural-dynamics-in-mild-cognitive-impairment-and-alzheimer-s-disease
#5
Jesús Poza, Carlos Gómez, María García, Miguel A Tola-Arribas, Alicia Carreres, Mónica Cano, Roberto Hornero
An accurate characterization of neural dynamics in mild cognitive impairment (MCI) is of paramount importance to gain further insights into the underlying neural mechanisms in Alzheimer's disease (AD). Nevertheless, there has been relatively little research on brain dynamics in prodromal AD. As a consequence, its neural substrates remain unclear. In the present research, electroencephalographic (EEG) recordings from patients with dementia due to AD, subjects with MCI due to AD and healthy controls (HC) were analyzed using relative power (RP) in conventional EEG frequency bands and a novel parameter useful to explore the spatio-temporal fluctuations of neural dynamics: the spectral flux (SF)...
March 9, 2017: Current Alzheimer Research
https://www.readbyqxmd.com/read/28289920/the-early-presentation-of-dementia-in-people-with-down-syndrome-a-systematic-review-of-longitudinal-studies
#6
REVIEW
Bianca Alexandra Lautarescu, Anthony John Holland, Shahid H Zaman
Adults with Down syndrome (DS) are at a very high risk of developing early onset Alzheimer's disease (AD) due to trisomy of chromosome 21. AD is preceded by a prolonged prodromal "pre-clinical" phase presenting with clinical features that do not fulfil the diagnostic criteria for AD. It is important to clinically characterise this prodromal stage to help early detection of the disease as neuropathology of AD is almost universal by the fifth decade in DS. There is a lack of knowledge of the trajectory of decline associated with the onset of dementia in this population and early signs may be overlooked or misdiagnosed, negatively affecting the quality of life of those affected and the use of early pharmacological or psychosocial interventions...
March 13, 2017: Neuropsychology Review
https://www.readbyqxmd.com/read/28282071/-new-predictors-in-prodromal-alzheimer-deferred-phase-in-word-recall-of-mis-test
#7
Edith Labos, Sofía Trojanowski, Marcelo Schapira, Daniel Seinhart, Alejandro Renato
BACKGROUND: The Memory Impairment Screen (MIS-A) is a validated test to detect Alzheimer's Disease (AD) and other dementias. We have modified this test to suit a Spanish speaking population and added a new component, delayed recall (MIS-D). OBJECTIVES: 1) To test a Spanish version of MIS-A and MIS-D. 2) To assess the discriminative validity of MIS-D as a screening tool for the amnestic variant of Mild Cognitive Impairment (aMCI). METHODS: A case-control study of a cohort of 739 aged 65 years old and over, of whom 436 were healthy controls and 303 had a diagnosis of aMCI...
September 2016: Vertex: Revista Argentina de Psiquiatriá
https://www.readbyqxmd.com/read/28281838/diagnostic-function-of-the-neuroinflammatory-biomarker-ykl-40-in-alzheimer-s-disease-and-other-neurodegenerative-diseases
#8
Filippo Baldacci, Simone Lista, Enrica Cavedo, Ubaldo Bonuccelli, Harald Hampel
Neuroinflammation is a crucial mechanism in the pathophysiology of neurodegenerative diseases pathophysiology. Cerebrospinal fluid (CSF) YKL-40 - an indicator of microglial activation - has recently been identified by proteomic studies as a candidate biomarker for Alzheimer's disease (AD). Areas covered: We review the impact of CSF YKL-40 as a pathophysiological biomarker for AD and other neurodegenerative diseases. CSF YKL-40 concentrations have been shown to predict progression from prodromal mild cognitive impairment to AD dementia...
March 20, 2017: Expert Review of Proteomics
https://www.readbyqxmd.com/read/28274325/consent-for-the-diagnosis-of-preclinical-dementia-states-a-review
#9
REVIEW
Julian C Hughes, Thomas A Ingram, Aron Jarvis, Elise Denton, Zoe Lampshire, Cathy Wernham
It is now possible to detect the pathology of Alzheimer's disease (AD) many years before symptoms and signs otherwise become manifest. Biomarkers of disease include evidence of amyloid and tau in the cerebrospinal fluid and neuroimaging which (for instance) allows amyloid in the brain to be visualized. There is, thus, a preclinical state in which it is possible to identify Alzheimer's pathology long before there is clinical evidence of disease. Much research focuses on this preclinical state because it seems likely that treatments will be more effective before the disease is established...
April 2017: Maturitas
https://www.readbyqxmd.com/read/28273828/association%C3%A2-of%C3%A2-serum%C3%A2-manganese%C3%A2-levels%C3%A2-with%C3%A2-alzheimer-s%C3%A2-disease%C3%A2-and%C3%A2-mild%C3%A2-cognitive%C3%A2-impairment-%C3%A2-a%C3%A2-systematic%C3%A2-review%C3%A2-and%C3%A2-meta-analysis
#10
Ke Du, Mingyan Liu, Yanzhu Pan, Xin Zhong, Minjie Wei
Manganese (Mn) is one of the most studied environmental heavy metals linked to Alzheimer's disease (AD). However, it remains unclear whether serum Mn levels are associated with AD and mild cognition impairment (MCI, a prodromal stage of AD). We conducted a metaanalysis to analyze the serum Mn levels in patients with AD and MCI. A systematic database search of PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI) identified 17 studies, including 836 cases and 1254 health controls (HC)...
March 3, 2017: Nutrients
https://www.readbyqxmd.com/read/28269787/cognitive-composites-domain-scores-related-to-neuroimaging-biomarkers-within-probable-amnestic-mild-cognitive-impairment-storage-subtype
#11
Ana Espinosa, Montserrat Alegret, Pedro Pesini, Sergi Valero, Asunción Lafuente, Mar Buendía, Itziar San José, Marta Ibarria, Miguel A Tejero, Joan Giménez, Susana Ruiz, Isabel Hernández, Francesc Pujadas, Pablo Martínez-Lage, Josep Munuera, Javier Arbizu, Lluis Tárraga, Suzanne B Hendrix, Agustín Ruiz, James T Becker, Susan M Landau, Oscar Sotolongo-Grau, Manuel Sarasa, Mercè Boada
The probable-amnestic (Pr-a) mild cognitive impairment (MCI)-storage subtype is a phenotype with 8.5 times more risk of conversion to dementia, mainly Alzheimer's disease (AD), than the possible non-amnestic (Pss-na) MCI. The aim of this study was to find the optimized cognitive composites (CCs) domain scores most related to neuroimaging biomarkers within Pr-aMCI-storage subtype patients. The Fundació ACE (ACE) study with 20 Pr-aMCI-storage subtype subjects (MCI) were analyzed. All subjects underwent a neuropsychological assessment, a structural MRI, FDG-PET, and PIB-PET...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28269781/cognitive-efficiency-in-alzheimer-s-disease-is-associated-with-increased-occipital-connectivity
#12
Matteo De Marco, Davide Duzzi, Francesca Meneghello, Annalena Venneri
There are cognitive domains which remain fully functional in a proportion of Alzheimer's disease (AD) patients. It is unknown, however, what distinctive mechanisms sustain such efficient processing. The concept of "cognitive efficiency" was investigated in these patients by operationalizing it as a function of the level of performance shown on the Letter Fluency test, on which, very often, patients in the early stages of AD show unimpaired performance. Forty-five individuals at the prodromal/early stage of AD (diagnosis supported by subsequent clinical follow-ups) and 45 healthy controls completed a battery of neuropsychological tests and an MRI protocol which included resting state acquisitions...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28253987/metabolic-syndrome-and-the-cellular-phase-of-alzheimer-s-disease
#13
S Pugazhenthi
Alzheimer's disease (AD) is characterized by cognitive dysfunction and progressive neurodegeneration. The major hallmarks of AD pathology are amyloid plaques and neurofibrillary tangles. However, AD often coexists with other brain microvascular lesions caused by comorbidities, including obesity, diabetes, hypertension, and cardiovascular diseases. The risk factors for these comorbidities are collectively referred to as metabolic syndrome (MetS). Clinical AD is preceded by decades of prodromal cellular phase...
2017: Progress in Molecular Biology and Translational Science
https://www.readbyqxmd.com/read/28223022/early-identification-of-mild-cognitive-impairment-using-incomplete-random-forest-robust-support-vector-machine-and-fdg-pet-imaging
#14
Shen Lu, Yong Xia, Weidong Cai, Michael Fulham, David Dagan Feng
Alzheimer's disease (AD) is the most common type of dementia and will be an increasing health problem in society as the population ages. Mild cognitive impairment (MCI) is considered to be a prodromal stage of AD. The ability to identify subjects with MCI will be increasingly important as disease modifying therapies for AD are developed. We propose a semi-supervised learning method based on robust optimization for the identification of MCI from [18F]Fluorodeoxyglucose PET scans. We extracted three groups of spatial features from the cortical and subcortical regions of each FDG-PET image volume...
February 7, 2017: Computerized Medical Imaging and Graphics: the Official Journal of the Computerized Medical Imaging Society
https://www.readbyqxmd.com/read/28210541/a-t1-and-dti-fused-3d-corpus-callosum-analysis-in-mci-subjects-with-high-and-low-cardiovascular-risk-profile
#15
Yi Lao, Binh Nguyen, Sinchai Tsao, Niharika Gajawelli, Meng Law, Helena Chui, Michael Weiner, Yalin Wang, Natasha Leporé
Understanding the extent to which vascular disease and its risk factors are associated with prodromal dementia, notably Alzheimer's disease (AD), may enhance predictive accuracy as well as guide early interventions. One promising avenue to determine this relationship consists of looking for reliable and sensitive in-vivo imaging methods capable of characterizing the subtle brain alterations before the clinical manifestations. However, little is known from the imaging perspective about how risk factors such as vascular disease influence AD progression...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28196556/approach-to-atypical-alzheimer-s-disease-and-case-studies-of-the-major-subtypes
#16
Bradford C Dickerson, Scott M McGinnis, Chenjie Xia, Bruce H Price, Alireza Atri, Melissa E Murray, Mario F Mendez, David A Wolk
Alzheimer's disease (AD) has long been recognized as a heterogeneous illness, with a common clinical presentation of progressive amnesia and less common "atypical" clinical presentations, including syndromes dominated by visual, aphasic, "frontal," or apraxic symptoms. Our knowledge of atypical clinical phenotypes of AD comes from clinicopathologic studies, but with the growing use of in vivo molecular biomarkers of amyloid and tau pathology, we are beginning to recognize that these syndromes may not be as rare as once thought...
February 15, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28188306/left-frontal-cortex-connectivity-underlies-cognitive-reserve-in-prodromal-alzheimer-disease
#17
Nicolai Franzmeier, Marco Duering, Michael Weiner, Martin Dichgans, Michael Ewers
OBJECTIVE: To test whether higher global functional connectivity of the left frontal cortex (LFC) in Alzheimer disease (AD) is associated with more years of education (a proxy of cognitive reserve [CR]) and mitigates the association between AD-related fluorodeoxyglucose (FDG)-PET hypometabolism and episodic memory. METHODS: Forty-four amyloid-PET-positive patients with amnestic mild cognitive impairment (MCI-Aβ+) and 24 amyloid-PET-negative healthy controls (HC) were included...
March 14, 2017: Neurology
https://www.readbyqxmd.com/read/28157093/bace1-dynamics-upon-inhibition-with-a-bace-inhibitor-and-correlation-to-downstream-alzheimer-s-disease-markers-in-elderly-healthy-participants
#18
Maarten Timmers, Soraia Barão, Bianca Van Broeck, Ina Tesseur, John Slemmon, Katja De Waepenaert, Jennifer Bogert, Leslie M Shaw, Sebastiaan Engelborghs, Dieder Moechars, Marc Mercken, Luc Van Nueten, Luc Tritsmans, Bart de Strooper, Johannes Rolf Streffer
The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimer's disease (AD) pathology. Increased BACE1 levels and activity have been reported in the brain of patients with sporadic AD. Therefore, changes of BACE1 levels in the cerebrospinal fluid (CSF) have also been investigated as a possible biomarker of the disease. We analyzed BACE1 levels in CSF of elderly healthy participants before and after chronic treatment with a BACE inhibitor (BACEi) and evaluated the correlation between BACE1 levels and downstream AD markers...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28149942/cognitive-complaints-in-older-adults-at-risk-for-alzheimer-s-disease-are-associated-with-altered-resting-state-networks
#19
Joey A Contreras, Joaquín Goñi, Shannon L Risacher, Enrico Amico, Karmen Yoder, Mario Dzemidzic, John D West, Brenna C McDonald, Martin R Farlow, Olaf Sporns, Andrew J Saykin
INTRODUCTION: Pathophysiological changes that accompany early clinical symptoms in prodromal Alzheimer's disease (AD) may have a disruptive influence on brain networks. We investigated resting-state functional magnetic resonance imaging (rsfMRI), combined with brain connectomics, to assess changes in whole-brain functional connectivity (FC) in relation to neurocognitive variables. METHODS: Participants included 58 older adults who underwent rsfMRI. Individual FC matrices were computed based on a 278-region parcellation...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28113456/sparse-multi-response-tensor-regression-for-alzheimer-s-disease-study-with-multivariate-clinical-assessments
#20
Zhou Li, Heung-Il Suk, Dinggang Shen, Lexin Li
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder that has recently seen serious increase in the number of affected subjects. In the last decade, neuroimaging has been shown to be a useful tool to understand AD and its prodromal stage, amnestic mild cognitive impairment (MCI). The majority of AD/MCI studies have focused on disease diagnosis, by formulating the problem as classification with a binary outcome of AD/MCI or healthy controls. There have recently emerged studies that associate image scans with continuous clinical scores that are expected to contain richer information than a binary outcome...
March 4, 2016: IEEE Transactions on Medical Imaging
keyword
keyword
92967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"